Wilsons endorse a valuation of $4.25 and a 12mnth price target of $4.80. In a research note released yesterday they emhasise that their valuation centres on market penetration for bronchitol. They base valuation on 10% market share after 2yrs. Management envisage this to be closer to 30%. Wilsons say if this is the case a valuation closer to $10 would be appropriate.
first broker upgrade: 5.10, page-5
-
- There are more pages in this discussion • 10 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
